Note 19. Interim Consolidated Financial Information (Unaudited)


	Fiscal 2018 Quarter Ended
(in thousands, except per share data)	March 31,		June 30,		September 30,		December 31,
Revenues(1)	$	382,282	$	521,516	$	449,683	$	528,402
Net income (loss)	$	(41,140)	$	52,394	$	29,176	$	69,063
Basic net income (loss) per share	$	(0.19)	$	0.25	$	0.14	$	0.32
Diluted net income (loss) per share	$	(0.19)	$	0.24	$	0.14	$	0.32
Shares used in computation of basic net income (loss) per share		211,681		212,210		212,627		213,013
Shares used in computation of diluted net income (loss) per share		211,681		215,103		215,964		216,042


	Fiscal 2017 Quarter Ended
(in thousands, except per share data)	March 31,		June 30,		September 30,		December 31,
Revenues(2)	$	384,082	$	326,444	$	381,534	$	444,156
Net income (loss)	$	(187,083)	$	(12,484)	$	36,054	$	(149,629)
Basic net income (loss) per share	$	(0.96)	$	(0.06)	$	0.17	$	(0.71)
Diluted net income (loss) per share	$	(0.96)	$	(0.06)	$	0.17	$	(0.71)
Shares used in computation of basic net income (loss) per share		195,260		205,141		206,796		211,125
Shares used in computation of diluted net income (loss) per share		195,260		205,141		212,610		211,125

(1)

The quarters ended March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018 include $334.5 million, $365.5 million, $367.7 million, and $399.2 million, respectively, of product revenues, net, relating to JAKAFI and ICLUSIG. The quarters ended March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018 include $47.7 million, $56.0 million, $61.9 million and $69.2 million, respectively, of product royalty revenues related to the sale of JAKAVI and OLUMIANT outside the United States. In November 2009 and December 2009, we entered into collaborative research and license agreements with Novartis and Lilly, respectively. The quarters ended March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018 include $0.0 million, $100.0 million, $20.0 million and $60.0 million, respectively, of milestone and contract revenues relating to these agreements.

(2)

The quarters ended March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017 include $264.8 million, $291.7 million, $322.0 million, and $321.8 million, respectively, of product revenues, net, relating to JAKAFI and ICLUSIG. The quarters ended March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017 include $29.2 million, $34.8 million, $44.5 million and $52.3 million, respectively, of product royalty revenues related to the sale of JAKAVI and OLUMIANT outside the United States. In November 2009 and December 2009, we entered into collaborative research and license agreements with Novartis and Lilly, respectively. The quarters ended March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017 include $90.0 million, $0.0 million, $15.0 million and $70.0 million, respectively, of milestone and contract revenues relating to these agreements.